BMAC on PCL Scaffold for Ridge Augmentation

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05241548
Collaborator
(none)
7
1
1
6.5
1.1

Study Details

Study Description

Brief Summary

BMAC is used on 3D printed PCL scaffold for horizontal ridge augmentation in aesthetic zone , BMAC contains MSCs which can differentiate in osteogenic medium into osteoblasts which can lay down bone

Condition or Disease Intervention/Treatment Phase
  • Procedure: BMAC on PCL Scaffold
N/A

Detailed Description

Alveolar bone defects were classified according to their morphology and pattern of bone loss into Class I where buccolingual loss occurs while maintaining the vertical height( Horizontal defect), Class II where vertical bone loss occurs with no buccolingual width loss (Vertical defect) and Class III where combination of vertical and horizontal bone loss occurs . These defects require augmentation before implant placement, several techniques were approached including autogenous and non autogenous bone grafting , Guided bone regeneration (GBR), ridge splitting and distraction osteogenesis. Bone grafts used with these techniques are categorized into : autografts, allografts , xenografts and alloplasts.

Autogenous bone is considered to be the gold standard in grafting because it is osteogenic in nature, osteoinductive , osteoconductive and immunologically safe The autogenous bone can be harvested intraorally from the chin area, mandibular ramus, retromolar area, maxillary tuberosity, Coronoid process, zygomatic bone or palatal and mandibular tori if present . Intraoral harvesting has the advantage of good access and no need for hospitalization but the main disadvantage is the donor site morbidity and the small amount of harvested bone. Extraoral harvesting sites include the ilium, calvarium, ribs, tibia and fibula. Extraoral harvesting solved the problem of the limited amount of harvested bone graft but the main disadvantages are the need of hospitalization, performing the harvesting procedure under general anesthesia and high morbidity due to the second surgical site Recently, tissue engineering has been used for bone regeneration so called bone tissue engineering (BTE) which aims to combine the progenitor cells to differentiate into osteoblasts, growth factors needed for regenerative process and osteoconductive scaffolds for therapeutic applications. BTE involves harvesting osteogenic cells from an autologous harvesting site ( bone marrow or adipose tissue) and/or ex vivo amplification and seeding the scaffold with cells for in vivo implantation aiming to replicate the properties of autogenous bone and decrease the need for invasive harvesting Bone marrow contains a heterogenous population of progenitor cells such as Mesenchymal stem cells (MSC),hematopoietic stem cells (HSC) and endothelial progenitor cells in addition to several growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-b), and bone morphogenetic protein (BMP)-2 and BMP-7, which are known to have anabolic and anti-inflammatory effects. Concentration of the mononuclear cell fraction (MNC) of bone marrow aspirate ( which includes MSCs) by density gradient centrifugation process to remove erythrocytes, granulocytes, platelets and immature myeloid precursors to form Bone Marrow Aspirate Concentrate (BMAC) is considered important step in BTE. .

Many clinical studies proved the use of Bone Marrow Aspirate Concentrate for treatment of osseous defects and cartilage defects due to the ability of MSCs to differentiate into osteoblasts, chondroblasts or adipocytes.

The mesenchymal stem cells (MSCs) are highly biologically competent as they possess the ability to adhere on plastic (scaffolds) in vitro, form colony forming fibroblasts (CFU) and differentiate into mesenchyme lineages ( adipocytes, osteocytes, chondrocytes, tenocytes, myocytes) in addition to their potential of self renewal and promotion of hematopoiesis. Also, they suppress alloresponse after transplantation .

Scaffolds are support structures used in tissue engineering to allow 3D growth of cells in an organized way and can be classified into natural (such as collagen plug) , synthetic aliphatic polyesters such as polycaprolactone (PCL), polyglycolic acid (PGA) and polylactic acid (PLA) and their copolymers and derivatives and composite scaffold which are made by combining bioceramics with polymers or xenogenic biomaterials together with bioceramics or polymers .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Bone Marrow Aspirate Concentrate(BMAC) on 3D Printed Polycaprolactone (PCL) Scaffold for Ridge Augmentation of Horizontal Alveolar Defects in Aesthetic Zone (Clinical Case Series Study)
Actual Study Start Date :
Jan 15, 2022
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Ridge augmentation of horizontally deficient alveolar ridge in aesthetic zone by BMAC on PCL scaffold

Procedure: BMAC on PCL Scaffold
Horizontal ridge augmentation in aesthetic zone by using bone marrow aspirate concentrate on PCL scaffold

Outcome Measures

Primary Outcome Measures

  1. Bone Width gain [6 months]

    The width of the augmented alveolar ridge measured from the Cone Beam Computed Tomography in millimeters

Secondary Outcome Measures

  1. Percentage of bone formation in the bone biopsy [6 months]

    Bone biopsy is obtained after 6 months and subjected to histomorphometric analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patient who require horizontal ridge augmentation in the aesthetic zone (Maxillary anterior and premolar area) with defect size of one or two lost teeth.

  • Patients in the age range of 18 years and above.

  • ASA physical status I and II.

  • Patients willing to be a part of the study and ready to give their consent in writing for the same.

Exclusion Criteria:
  • Local criteria:

  • Untreated gingivitis, periodontitis.

  • Insufficient oral hygiene.

  • Previous radiation therapy the head and neck neoplasia, or bone augmentation to implant site.

Systemic criteria:
  • Systemic disorders.

  • Smoking.

  • Bone pathology.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of Dentistry, Cairo university Cairo Egypt 12311

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Alaa Aly Hassan Fouad, Resident doctor, Cairo University
ClinicalTrials.gov Identifier:
NCT05241548
Other Study ID Numbers:
  • BMAC 3D PCL
First Posted:
Feb 15, 2022
Last Update Posted:
Feb 15, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alaa Aly Hassan Fouad, Resident doctor, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2022